EUCTR2012-001821-28-ES进行中（未招募）不适用
A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen, Inc.
- 入组人数
- 620
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Subject or subject?s legally acceptable representative has provided informed consent prior to any study specific procedure(s)
- •- Ambulatory postmenopausal women. Ambulatory is defined as women who are able to walk, not bedridden; postmenopause is defined as no vaginal bleeding or spotting for at least 12 months prior to screening.
- •- Age 55 years or older
- •- Received oral bisphosphonate therapy for OP for at least 2 years immediately prior to screening visit
- •- Screening BMD (g/cm2) values at the lumbar spine, total hip or femoral neck; values of equal to or less than those listed in the protocol. Eligibility will be determined by a local reading of the DXAs at the investigator site. At least 2 lumbar vertebrae and one hip must be evaluable by DXA at the screening visit.
- •- Serum CTX value of <= 0.5 ng/mL at the screening visit as determined by central laboratory
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 440
排除标准
- •- Height, weight or girth which may preclude accurate DXA measurements
- •- Received other OP treatment or bone active treatment with the following guidelines
- •.administration of denosumab or zoledronic acid at any time
- •.administration of the following within the last 5 years
- •..IV bisphosphonate other than zoledronic acid
- •..fluoride or strontium at doses approved for OP
- •..PTH or PTH derivatives within the last year
- •- Abnormalities of the following per central laboratory reference ranges:
- •.vitamin D deficiency (25[OH] vitamin D level < 20 ng/mL), repletion will be allowed and subjects may be re-screened
- •.hypercalcemia
- •.elevated transaminases >= 2.0 x upper limits of normal (ULN)
- •- Administration of any of the following treatment within 3 months of screening:
- •.any selective estrogen receptor modulator (estrogen agonist antagonist)
- •.anabolic steroids or testosterone
- •.glucocorticosteroids (>= 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of >= 50 mg)
- •.systemic hormone replacement therapy (HRT) (subjects stable on HRT for more than 3 months prior is permitted)
- •.calcitonin
- •.other bone active drugs including anti-convulsants (except
- •benzodiazepines) and heparin
- •.cathepsin K inhibitor
- •.anti-sclerostin antibody
- •.chronic systemic ketoconazole, androgens, adrenocorticotrophic hormone, cinacalcet, aluminum, lithium, protease inhibitors, gonadotropin- releasing hormone agonists
- •- Evidence of history of any of the following:
- •.hyperthyroidism (stable on antithyroid therapy is allowed)
- •.hypothyroidism (stable on thyroid replacement therapy is allowed)
- •.hypo- or hyperparathyroidism
- •.hypo- or hypercalcemia based on the central laboratory reference ranges
- •.known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen
- •.osteomalacia (chart review)
- •.osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease
- •.recent tooth extraction (within 6 months of screening visit)
- •.Paget disease of bone (subject report or chart review)
- •.other bone diseases which affect bone metabolism (eg, osteopetrosis, osteogenesis imperfecta) (chart review)
- •- History of any solid organ or bone marrow transplant
- •- Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in situ) within the last 5 years
- •- Contraindicated or poorly tolerant of denosumab therapy; contraindications include
- •.hypocalcemia
- •.hypersensitivity to drug or any component of the drug
- •- Contraindicated or poorly tolerant of zoledronic acid therapy; contraindications include the following:
- •.hypocalcemia
- •.subjects with creatinine clearance of <35 mL/min and in those with evidence of acute renal impairment (calculated using Cockcroft Gault equation)
- •.hypersensitivity to any component of zoledronic acid solution
- •- Known intolerance to calcium or vitamin D supplements
- •- For women of child bearing potential: refusal to use 2 highly effective forms of contraception and to continue this practice for 7 months after last injection of study medication
- •- Self-reported alcohol or drug abuse within 12 months prior to screening
- •- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)
- •- Other investigational procedures while pa
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesPost Menospausal OsteoporosisMedDRA version: 17.0Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-001821-28-BEAmgen, Inc.620
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesEUCTR2012-001821-28-DKAmgen, Inc.620
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesEUCTR2012-001821-28-PLAmgen, Inc.620
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesPost Menospausal OsteoporosisMedDRA version: 15.0Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-001821-28-DEAmgen, Inc.620
进行中（未招募）
不适用
A Randomised, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects with Ankylosing Spondylitis - ASCENDEUCTR2005-001549-41-DEWyeth Research Division of Wyeth Pharmaceuticals Inc540